EasyDNNNews

USPSTF updates recommendations on risk-reducing breast cancer medications

Tuesday, September 3, 2019

Radiology Business (9/3, Walter) reports that healthcare providers should offer risk-reducing medications such as tamoxifen, raloxifene and aromatase inhibitors to women at an increased risk of breast cancer or low risk of experiencing adverse effects, according to the recommendations published by the U.S. Preventive Services Task Force (USPSTF).

Radiologists ready to speak with patients about breast density, supplemental screening

Tuesday, September 3, 2019

Radiology Business (9/3, Walter) reports that many radiologists believe patient-provider discussions about screening mammography and supplemental screening are inadequate, according to findings published in the Journal of Breast Imaging. The specialty appears ready to step up and take a more visible role in patient education.

Cities in New England have highest breast screening rates

Thursday, August 22, 2019

Aunt Minnie (8/22, Madden Yee) reports that not just rural areas that are susceptible to disparities in screening mammography, but cities too -- with metropolitan areas in New England having the highest rates of mammography use, while cities in the Mountain region have the lowest, according to a study published in Radiology.

USPSTF updates BRCA cancer screening recommendations

Tuesday, August 20, 2019

The Health Imaging (8/20, O'Connor) reports that the U.S. Preventative Services Task Force (USPSTF) released updated recommendations for BRCA1/2 testing, suggesting practitioners increase the use of genetic counseling and testing. Specifically, the USPSTF recommends clinicians assess women with a personal or family history of breast, ovarian, tubal or peritoneal cancer associated with BRCA gene mutations using a brief risk assessment tool.

AI solution distinguishes complex pathologies for accurate breast cancer diagnosis

Thursday, August 15, 2019

Health Care Business News (8/15) reports on a new study from the journal JAMA Network Open that details a new AI solution that can distinguish between hard-to-read pathologies, such as ductal carcinoma in situ (CDIS) and atypia.

RSS
135678910Last

Theme picker